Nyxoah Raises $95M by Selling 55.2M Shares at $1.72 to Fund Genio Expansion
NYXH•Nyxoah issued 55,232,558 shares at $1.72 apiece in its US offering, raising approximately $95.0 million gross. Net proceeds will expand US Genio system commercialization, fund R&D upgrades, support EU market launches and clinical studies, and cover corporate needs, alongside a planned EUR13.8 million EIB loan draw in Q2.
1. Offering Details
Nyxoah completed an underwritten public offering of 55,232,558 ordinary shares in the United States at $1.72 per share, generating gross proceeds of approximately $95.0 million before underwriting discounts, commissions and expenses. The offering also included private placements to qualified institutional investors outside the US, broadening its shareholder base.
2. Use of Proceeds
Net proceeds will support expansion of Genio system commercialization in the US and initial target markets outside the US, fund ongoing R&D initiatives such as system upgrades, manufacturability redesign and cost reductions, and back clinical data gathering and physician-initiated research projects for obstructive sleep apnea treatment.
3. Financing and Strategic Outlook
In addition to the offering, Nyxoah plans to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026. Funds will also cover working capital, debt repayment, capital expenditures, potential acquisitions and collaborations aimed at strengthening its position in the sleep apnea therapy market.
